Aurobindo Pharma incurring loss at China Plant; hopes to achieve break-even by Q4

Aurobindo Pharma's China facility is set to achieve break-even by the end of fiscal year 2026. The company anticipates significant growth driven by its Pen-G facility ramp-up and biosimilar portfolio commercialization. The US market will see contributions from the Dayton facility starting January. Aurobindo aims for a 20-21 percent margin target for FY26.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/HV0z9u1
via IFTTT